RESUMEN
Hedgehog (Hh) pathway is involved in epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) maintenance resulting in tumor progression. GDC-0449, an inhibitor of Hh pathway component smoothened (Smo) has shown promise in the treatment of various cancers including pancreatic cancer. However, the emergence of resistance during GDC-0449 treatment with numerous side effects limits its use. Therefore, here we report the design, synthesis and evaluation of novel GDC-0449 analogs using N-[3-(2-pyridinyl) phenyl] benzamide scaffold. Cell-based screening followed by molecular simulation revealed 2-chloro-N 1-[4-chloro-3-(2-pyridinyl)phenyl]-N 4,N 4-bis(2-pyridinylmethyl)-1,4-benzenedicarboxamide (MDB5) as most potent analog, binding with an extra interactions in seven-transmembrane (7-TM) domain of Smo due to an additional 2-pyridylmethyl group than GDC-0449. Moreover, MDB5 was more efficient in inhibiting Hh pathway components as measured by Gli-1 and Shh at transcriptional and translational levels. Additionally, a significant reduction of ALDH1, CD44 and Oct-3/4, key markers of pancreatic CSC was observed when MIA PaCa-2 cells were treated with MDB5 compared to GDC-0449. In a pancreatic tumor mouse model, MDB5 containing nanoparticles treated group showed significant inhibition of tumor growth without loss in body weight. These evidence highlight the enhanced Hh pathway inhibition and anticancer properties of MDB5 leaving a platform for mono and/or combination therapy.
Asunto(s)
Antineoplásicos/síntesis química , Antineoplásicos/uso terapéutico , Diseño de Fármacos , Proteínas Hedgehog/antagonistas & inhibidores , Neoplasias Pancreáticas/tratamiento farmacológico , Anilidas/química , Animales , Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Biomarcadores de Tumor/metabolismo , Carcinogénesis/patología , Puntos de Control del Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Movimiento Celular/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Proteínas Hedgehog/metabolismo , Humanos , Concentración 50 Inhibidora , Masculino , Ratones , Simulación del Acoplamiento Molecular , Nanopartículas/química , Células Madre Neoplásicas/efectos de los fármacos , Células Madre Neoplásicas/metabolismo , Células Madre Neoplásicas/patología , Especificidad de Órganos/efectos de los fármacos , Neoplasias Pancreáticas/patología , Piridinas/química , Receptor Smoothened , Esferoides Celulares/efectos de los fármacos , Esferoides Celulares/metabolismo , Esferoides Celulares/patología , Relación Estructura-ActividadRESUMEN
OBJECTIVE: To study the effect of Yisui Tongjing (YSTJ) prescription on motor nerve conduction velocity (MNCV) and microstructure of the sciatic nerve in experimental autoimmune neuritis (EAN) rats, the Guillain-Barré syndrome classic animal models. MATERIALS AND METHODS: In this study, we established an EAN model in Lewis rats by immunization. We evaluated the potential clinical application of a traditional Chinese medicine YSTJ by intragastric administration and compared its effect with immunoglobulin. The sciatic MNCV was measured by electrophysiology experiment. Hematoxylin-eosin staining and transmission electron microscope analysis were used to determine the pathologically morphological changes before and after YSTJ application. RESULTS: We found that application of YSTJ could significantly alleviate the clinical signs in EAN rats. The treatment also increased MNCV in the sciatic nerve compared to that in the untreated nerve. Demyelination in the sciatic nerve in EAN rats was significantly ameliorated, and newly generated myelinated nerve fibers were observed with treatment of high dose of YSTJ. CONCLUSION: This study showed that the traditional Chinese medicine YSTJ was likely to serve as a therapeutic medicine in autoimmune neuropathies, providing an effective and economic means to the treatment of Guillain-Barré syndrome.
RESUMEN
This paper describes a method for a single-step, site-specific conjugation of bioactive peptides to proteins that exploits the monitoring advantages provided by the unique UV signature absorbance of a bis-arylhydrazone. The utility of this method is demonstrated by the conjugation of a decapeptide molecular adjuvant, YSFKDMP(MeL)aR (EP67), to two test proteins, ovalbumin (OVA) and bovine serum albumin (BSA), and to proteins expressed on intact influenza virons and fungal arthroconidia (spores) of Coccidioides. Conjugation is accomplished with a version of EP67 in which its N-terminus is modified with succinimidyl-4-benzoylhydrazino-nicotinamide (S4BHyNic) (peptide 7), thus enabling conjugation to these large entities via formation of amide bonds with surface-exposed amino groups. The presence of the strongly absorbing bis-arylhydrazone S4BHyNic (ε(354 nm) = 29 000 L mol(-1) cm(-1)) allows for determination of EP67-to-protein molar substitution ratios (MSR), which are in good agreement with the MSRs determined by amino acid analysis. Conjugation to OVA does not compromise the ability of EP67 to engage C5a receptor bearing antigen presenting cells (APC) as measured by the EP67-mediated release of interleukin-6 (IL-6) from APCs. Mice immunized with the resulting OVA-EP67 vaccine conjugate produce high serum titers of OVA-specific IgG antibodies relative to OVA alone. Also, the conjugation of EP67 does not affect the surface integrity of influenza virons or the biological viability of Coccidioides spores. This method of conjugating bioactive peptides to proteins and other large biological entities may represent a convenient and effective way of generating various bioconjugates for use in mechanistic studies or novel therapeutic entities such as EP67-containing vaccines.
Asunto(s)
Adyuvantes Inmunológicos/química , Células Presentadoras de Antígenos/efectos de los fármacos , Células Presentadoras de Antígenos/inmunología , Coccidioides/inmunología , Hidrazonas/química , Interleucina-6/análisis , Niacinamida/química , Orthomyxoviridae/inmunología , Ovalbúmina/química , Ovalbúmina/inmunología , Albúmina Sérica Bovina/química , Albúmina Sérica Bovina/inmunología , Succinimidas/química , Vacunas/química , Vacunas/inmunología , Animales , Femenino , Humanos , Ratones , Ratones Endogámicos BALB C , Oligopéptidos/síntesis química , Oligopéptidos/inmunología , Oligopéptidos/farmacología , Esporas Fúngicas , VacunaciónRESUMEN
Triclabendazole is the drug of choice against Fasciola hepatica infections in humans and animals. However, parasite resistance against triclabendazole is spreading in the veterinary field, and there are no drugs of comparable activity currently available for the treatment and control of fascioliasis. We investigated the efficacy of single oral doses of artemether and OZ78 against adult triclabendazole-resistant F. hepatica harboured in rats, and compared the results with triclabendazole administered at two different doses. Single oral doses of 100 mg/kg OZ78 and 200 mg/kg artemether resulted in worm burden reductions of 100%. Whereas a single 10 mg/kg dose of triclabendazole achieved a worm burden reduction of only 4.0%, a five-fold higher dose yielded a significant worm burden reduction of 60.9%. However, the lower dose of triclabendazole administered to rats harbouring a triclabendazole-sensitive F. hepatica isolate resulted in a worm burden reduction of 95.3%. Our findings confirm that artemether and OZ78 possess good fasciocidal properties, even against a triclabendazole-resistant F. hepatica isolate, and hence these drugs might become useful in areas where triclabendazole resistance is common.
Asunto(s)
Adamantano/análogos & derivados , Antiplatelmínticos/uso terapéutico , Artemisininas/uso terapéutico , Fasciola hepatica/efectos de los fármacos , Fascioliasis/tratamiento farmacológico , Adamantano/uso terapéutico , Administración Oral , Animales , Arteméter , Bencimidazoles/uso terapéutico , Conductos Biliares/parasitología , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Resistencia a Medicamentos , Femenino , Masculino , Ratas , Ratas Sprague-Dawley , Ratas Wistar , TriclabendazolRESUMEN
OBJECTIVE: To test and verify the transient therapeutic effect of acupuncture at point "Qingchuan" on bronchial asthma. METHODS: Two hundred cases of bronchial asthma at acute attack stage were divided into a trial group of 100 cases treated with acupuncture at point "Qingchuan" and a control group of 100 cases treated with acupuncture at Dingchuan (EX-B1). RESULTS: The total effective rate was 92.60% and the effect occurred within 42-860 seconds after acupuncture in the trial group, and 81.0% and within 114-126 seconds in the control group, respectively, with very significant differences between the two groups (P < 0.01, P < 0.001). CONCLUSION: Acupuncture at point "Qingchuan" can significantly improve asthmatic state in the patient of bronchial asthma with action of rapidly stopping asthma.
Asunto(s)
Terapia por Acupuntura , Asma , Puntos de Acupuntura , Asma/terapia , HumanosRESUMEN
OBJECTIVE: To evaluate clinical therapeutic effect of acupuncture at Fengchi (GB 20) and Tianzhu (BL 10) on vertebrobasilar insufficiency (VBI). METHODS: One hundred and sixteen cases of VBI were randomly divided into 2 groups, 58 cases in each group. The treatment group were treated with acupuncture at Fengchi (GB 20) and Tianzhu (BL 10), and the control group with oral administration of Nimodipine. Clinical symptoms, and the average blood flow rates of left vertebral artery (LVA), right vertebral artery (RVA) and basilar artery (BA) detected by transcranial Doppler's method (TCD) before and after treatment were investigated. RESULTS: The total effective rate was 89.66% in the treatment group and 86.21% in the control group. Acupuncture had significantly therapeutic effect in improvement of clinical symptoms and the average blood flow rate of BA, better than Nimodipine. CONCLUSION: Acupuncture at Fengch; (GB 20) and Tianzhu (BL 10) has obvious therapeutic effect on vertebrobasilar insufficiency.
Asunto(s)
Puntos de Acupuntura , Terapia por Acupuntura , Arteria Basilar , Humanos , Arteria Vertebral , Insuficiencia Vertebrobasilar/terapiaRESUMEN
The discovery of artemisinin more than 30 years ago provided a completely new antimalarial structural prototype; that is, a molecule with a pharmacophoric peroxide bond in a unique 1,2,4-trioxane heterocycle. Available evidence suggests that artemisinin and related peroxidic antimalarial drugs exert their parasiticidal activity subsequent to reductive activation by haem, released as a result of haemoglobin digestion by the malaria-causing parasite. This irreversible redox reaction produces carbon-centred free radicals, leading to alkylation of haem and proteins (enzymes), one of which--the sarcoplasmic-endoplasmic reticulum ATPase PfATP6 (ref. 7)--may be critical to parasite survival. Notably, there is no evidence of drug resistance to any member of the artemisinin family of drugs. The chemotherapy of malaria has benefited greatly from the semi-synthetic artemisinins artemether and artesunate as they rapidly reduce parasite burden, have good therapeutic indices and provide for successful treatment outcomes. However, as a drug class, the artemisinins suffer from chemical (semi-synthetic availability, purity and cost), biopharmaceutical (poor bioavailability and limiting pharmacokinetics) and treatment (non-compliance with long treatment regimens and recrudescence) issues that limit their therapeutic potential. Here we describe how a synthetic peroxide antimalarial drug development candidate was identified in a collaborative drug discovery project.
Asunto(s)
Antimaláricos/síntesis química , Antimaláricos/farmacología , Artemisininas/química , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Compuestos Heterocíclicos con 1 Anillo/síntesis química , Compuestos Heterocíclicos con 1 Anillo/farmacología , Peróxidos , Sesquiterpenos/química , Compuestos de Espiro/síntesis química , Compuestos de Espiro/farmacología , Animales , Antimaláricos/química , Antimaláricos/farmacocinética , Disponibilidad Biológica , Semivida , Compuestos Heterocíclicos con 1 Anillo/química , Compuestos Heterocíclicos con 1 Anillo/farmacocinética , Humanos , Concentración 50 Inhibidora , Malaria/tratamiento farmacológico , Malaria/metabolismo , Malaria/parasitología , Ratones , Oxidación-Reducción , Plasmodium berghei/efectos de los fármacos , Plasmodium berghei/fisiología , Plasmodium falciparum/efectos de los fármacos , Ratas , Ratas Wistar , Solubilidad , Compuestos de Espiro/química , Compuestos de Espiro/farmacocinética , Distribución TisularRESUMEN
This review describes mechanisms of action of artemisinin-related antimalarials, emphasizing the site and target of activation, pathways of generating reactive species, and possible targets of free radicals with implications for antimalarial peroxide drug design. It also presents a useful link between the mode of action of artemisinin and that of chloroquine, and highlights redox cycles involved in the interaction between the drug and vital biomolecules.